Loading market movers...

Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.

Phase 3

TAKEDA PHARMACEUTICAL CO LTD (TAK)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

3

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

6 competitors in Hypertension

NVSBenazepril plus hydrochlorothiazide

ALNYZilebesiran

View Full Landscape

Drug Information

Target Indication

Hypertension

Clinical Trial

Last updated: 2/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/23/2019

Giapreza

Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

EMA12/7/2011

Edarbi

Edarbi is indicated for the treatment of essential hypertension in adults.

EMA12/7/2011

Ipreziv

Ipreziv is indicated for the treatment of essential hypertension in adults.

Drug Science

Mechanism of action & safety profile

Developer

TAK

TAKEDA PHARMACEUTICAL CO LTD

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

REPLAGALPhase 3

Fabry Disease

Alogliptin and pioglitazonePhase 3

Type 2 Diabetes Mellitus

Primary Immunodeficiency Diseases (PID)

IGSC 20% infusionPhase 3

Primary Immunodeficiency Disease

Lapaquistat acetate and atorvastatinPhase 3

Hypercholesterolemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts